/
INCY
$120.16-$0.36 (-0.30%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$24.5B
203M shares
52-week range
$81.09 – $132.60
76% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
CS
Change+$46.17
Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
www.incyte.com- Employees
- 2,844
- IPO / List date
- Nov 3, 1993
- HQ
- WILMINGTON, DE
Held by traders on TradeandTell
No one on the platform currently holds INCY.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 3,651,532 | $343.7M |
| Bridgewater Associatesas of 2026-03-31 | 130,296 | $12.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded INCY yet.
